CellRapeutics™ In Vivo B Cell Engineering Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The Prospect of In Vivo B Cell Engineering

Ex vivo engineering of B cells to produce target-specific antibodies has proven to be an effective pathway for treating disease. However, there are some limitations to the specific application of this strategy, such as the complex procedures ex vivo, and MHC compatibility between donor and recipient cells. To address these issues, in vivo B cell engineering serves as a safer, cost-effective, and scalable approach to producing targeted therapeutic antibodies.

Fig.1 Ex vivo B cell engineering. (Kleinboehl, et al., 2022)

Our CellRapeutics™ In Vivo B Cell Engineering Service

With our superior technology platform, Creative Biolabs specializes in providing cost-effective CellRapeutics™ in vivo B cell engineering services for global customers. Our CellRapeutics™ in vivo B cell engineering service incorporates cutting-edge technologies such as CRISPR/Cas9 to integrate the coded genes and engineered viral vectors such as AAV into a desired site in the B cell genome. In addition, we offer a full range of high-quality in vivo B cell engineering services, including vector optimization, and animal model establishment, to generate compelling data to suitable for our clients' B cell research and project development.

Fig.2 Anti-HIV-1 broadly neutralizing antibodies induced by natural immunity, trained immunity, and engineered immunity. (Sun, et al., 2023)

Highlight Features

Published Data

Representative data: These grants reveal, for the first time, that B cells may be safely and robustly created in vivo. In mice, a single systemic dosage of dual AAV-DJ coding for CRISPR-Cas9 and donor cassettes enabled site-specific integration with little off-target Cas9 expression and DNA double-strand breaks. Following immunization, the engineered B cells were activated by antigens, resulting in memory retention, clonal selection, and differentiation into plasma cells that release neutralizing amounts of bNAb.

Fig.3 In vivo B cell engineering expressing an anti-HIV bNAb. (Nahmad, et al., 2022)

Frequently Asked Question

Q1: Can in vivo engineered B cells be used to generate therapeutic antibodies?

A1: In vivo B cell engineering is a safe, potent, and scalable technology that might be used to treat not just infectious diseases but also noncommunicable diseases including cancer and autoimmune disease.

For more details about our CellRapeutics™ in vivo B cell engineering service, please contact us with no hesitation. We are sincerely looking forward to working with global customers.

References

Kleinboehl, E.; et al. Primary B cell engineering for therapeutic research. Trends Mol Med. 2022, 28(6): 528-529.
Sun, C.; et al. B cell engineering in vivo: Accelerating induction of broadly neutralizing antibodies against HIV-1 infection. Signal Transduct Target Ther. 2023, 8(1): 13.
Nahmad, A.D.; et al. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat Biotechnol. 2022, 40(8):1241-1249.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION